INTRODUCTION
============

Chronic hepatitis B (CHB) remains a serious global public health issue^[@B1]\ -\ [@B5]^. According to data from the World Health Organization (WHO), an estimated 257 million people are infected with hepatitis B virus (HBV)^[@B3]^. Mother-to-child transmission (MTCT) is the major cause of CHB infection^[@B3],\ [@B6],\ [@B7]^. Prevention of HBV MTCT could therefore reduce the number of new HBV carriers. In addition, if HBV is left untreated, the risk of chronicity will depend on the age at which the patient acquired the infection (80-90% in newborns and\< 5% in adults)^[@B8]^. Compared to the acute hepatitis B infection, CHB is more likely to result in severe long-term life-threatening complications, including cirrhosis and hepatocellular carcinoma. In 2015, 887,000 deaths were reported and attributed to HBV complications^[@B9]^. Therefore, preventing MTCT could effectively decrease deaths related to CHB.

Recently, infants have been subjected to active and passive immune prophylactic measures, called timely HepB-BD, and the WHO recommends completion of the HBV vaccine schedule as a mainstream procedure to prevent HBV vertical transmission^[@B6]^. However, 5-10% of newborns are still infected by their HBV-positive mothers^[@B4],\ [@B10]^. Infants born to mothers with high viral load (more than 10^[@B6]^ copies/mL) and hepatitis B envelope antigen (HBeAg) positivity showed 10-30% immune prophylaxis failure, while those born to mothers with low maternal viral load (less than 10^[@B6]^ copies/mL) show less than 3% failure^[@B8],\ [@B10]^. Thus, antiviral intervention for pregnant women with high maternal HBV-DNA levels will help to achieve a global eradication of CHB infection^[@B10]\ -\ [@B12]^.

Although a consensus on the use of antiviral drugs to interrupt HBV MTCT has been reached, the proper timing of antiviral treatment during pregnancy remains controversial. Antiviral therapy is typically administered in the second and third trimesters of gestation. According to the American Association for the Study of Liver Diseases (AASLD)^[@B13]^ and the Asian Pacific Association for the Study of the Liver (APASL)^[@B14]^, the starting point for maternal treatment should be at 28-32 weeks of gestation. The European Association for the Study of the Liver (EASL)^[@B15]^ and the Chinese Medical Association^[@B15],\ [@B16]^ recommend treatment initiation at 24-28 weeks of gestation. However, related cohort studies with large sample sizes and randomized controlled trials (RCTs) are still lacking. Therefore, a systematic review and meta-analysis was conducted to compare the efficacy of antiviral therapy for HBV MTCT prevention in the second or in the third trimester.

METHODS
=======

Search strategy
---------------

A comprehensive search of PubMed, Embase, the Cochrane Library, Ovid MEDLINE, Web of Science, SinoMed, the China National Knowledge Infrastructure (CNKI), the China Science and Technology Journal Database and the Wanfang Database was conducted from January 2013 to December 2018. The following search terms and their variations were used: "pregnant or mother", "hepatitis B virus or HBV or chronic hepatitis B or CHB", "antiviral or lamivudine or LAM or telbivudine or LdT or tenofovir or TDF", "mother-to-child or MTCT or vertical or mother-to-fetus or maternal-neonatal" and "infection or transmission or prevention or control". No language restrictions were applied. The reference lists were reviewed to identify additional articles.

Eligibility criteria
--------------------

Studies were included if they met the following inclusion criteria: 1) they were RCTs or cohort studies; 2) they included pregnant women with HBV infections who had accepted antiviral therapy during pregnancy; 3) they included only infants who received one dose of HBIG at birth and three doses of hepatitis B vaccine at birth or after delivery and 4) they included data on the MTCT rate.

MTCT was considered to have occurred if HBsAg positivity was observed or if HBV-DNA levels were detectable when the infants were seven to 12 months old.

The following types of studies were excluded: 1) case reports, review articles, letters to the editor, editorials and conference abstracts; 2) studies in which patients were coinfected with HIV, HCV or HDV, or patients were not pregnant women; 3) studies in which patients received a combined-HBIG injection during pregnancy or 4) studies in which antiviral therapy was initiated before pregnancy or during early pregnancy (before the second trimester).

Data extraction
---------------

Two independent investigators examined the titles and abstracts. The full-text versions of the included articles were then reviewed, following the same procedure. Disagreements were reconciled by a third person. The following information was extracted from each study: authorship, publication year, the age of subjects (years), maternal HBV-DNA levels before antiviral intervention and prior to delivery, baseline ALT level, intervention and control subject numbers, the time of treatment onset (in gestational weeks), the time of treatment discontinuation (in postpartum weeks), the study design and MTCT rates. In the included trials, the second trimester referred to 13-27 weeks of gestation, while the third trimester referred to the period beginning at 28 weeks of gestation. The specific weeks of gestation during which antiviral therapy was initiated and the average duration of antiviral treatment were obtained directly from the articles. The outcomes were the maternal HBV-DNA levels at delivery and the MTCT rate. The different groups of maternal HBV-DNA level were further divided into subgroups according to their specific antiviral initiation time. MTCT was considered to have occurred if HBsAg positivity was observed or if HBV-DNA levels were detectable when the infants were seven to 12 months old. Then, two analyses were carried out according to subgroups: the analysis on the differences in efficacy among various antiviral initiation times and the analysis on the differences in MTCT rates when HBsAg with respect to HBV-DNA seropositivity was used as the outcome.

Risk of bias assessment
-----------------------

The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the included observational studies. NOS involves a total of eight items divided into three categories: selection (4), comparability (1) and exposure (3). The scale ranges from zero to nine points. The studies that met the requirements were awarded the corresponding numbers of points. A maximum of two stars were given for the comparability parameter. A study with a score of more than 5 points was considered of high quality.

Statistical analysis
--------------------

We performed the review and meta-analysis according to the recommendations of the Cochrane Collaboration. To create forest plots, we calculated the risk ratio (RR) and 95% confidence interval (95% CI) using a binomial distribution for dichotomized outcomes, and we determined the weighted mean difference (WMD) with 95% CI for continuous outcomes. Before we analyzed the data, we tested the heterogeneity among the included studies by means of the chi-square test and *I* ^2^ statistic. *P* \<0.05 for the chi-square test or an *I* ^2^\>50% were considered as indicative of high heterogeneity. If high heterogeneity was observed, a random effect model (DerSimonian-Laird method) was used to analyze the data. In the absence of significant heterogeneity, a fixed model (Mantel-Haenszel method) was applied. When considerable heterogeneity was found, a sensitivity analysis was performed by omitting one study in each iteration to explore the influence of a single study on the overall estimate. A *P* value less than 0.05 was judged as statistically significant. All statistical analyses were conducted using the Review Manager software, version 5.3 (Cochrane Collaboration, Copenhagen, Denmark.

RESULTS
=======

The search strategy identified 6,232 papers. After 1,777 duplicate articles were removed, 4,455 articles remained, 4,414 of which were excluded on the basis of the title and abstract. Then, the full texts of the remaining 41 studies were examined. Thirty-two studies were removed: 12 were related to drug withdrawal; 11 were review articles, conference abstracts or reports; seven involved different interventions and two reported different outcomes of interest. Ultimately, nine studies that met the inclusion criteria were included in this meta-analysis.

Characteristics of the included studies
---------------------------------------

The details of the study selection process are described in [Figure 1](#f01){ref-type="fig"}. All the included articles were observational cohort studies. The majority of these studies were reported in Chinese (n=5)^[@B17]\ -\ [@B21]^, while four^[@B22]\ -\ [@B25]^ were reported in English. Overall, nine studies that enrolled a total of 1,502 mothers were included. Most of these studies used telbivudine (LdT) and tenofovir disoproxil fumarate (TDF). All of the infants were born in China and received active and passive combined immunization with 100 IU HBIG once in the neonatal period and hepatitis B vaccine three times, at zero, one and six months postpartum.

Figure 1Flow diagram of the study selection process.

Predelivery maternal HBV-DNA levels (log10 scale) after treatment initiation in the second trimester compared with the third trimester
--------------------------------------------------------------------------------------------------------------------------------------

All the articles^[@B17]\ -\ [@B25]^ provided detailed descriptions on the maternal HBV-DNA levels before intervention ([Table 1](#t1){ref-type="table"}). There were no statistically significant differences in maternal HBV-DNA levels (log~10~ scale) before treatment between mothers who began the antiviral therapy in the second trimester and those who began it in the third trimester *(I* ^2^=0%, *P* =0.25, [Table 2](#t2){ref-type="table"}). Only six studies^[@B18]\ -\ [@B21],\ [@B23],\ [@B25]^ reported maternal HBV-DNA levels prior to delivery. The pre-delivery maternal HBV-DNA levels (log~10~ scale) differed significantly ( *P* \<0.001) between the two groups, with distinguished heterogeneity (*P* \<0.001, *I* ^2^=82%, [Table 3](#t3){ref-type="table"}). Therefore, we performed the subgroups analysis according to the different drug treatment initiation times ([Table 4](#t4){ref-type="table"}), which reduced the heterogeneity (*I* ^2^=0% for each subgroup), and evaluated the stability of the results. The results indicated that beginning the antiviral therapy in the second trimester significantly reduced the HBV-DNA levels in HBV-infected mothers ( *P* \<0.01 for most subgroup, *WMD* =--0.93, *95% CI* -1.08-0.77).

Table 1Characteristics of the studies included in the meta-analysis.Study or subgroupAge (years) (Intervention/control)Baseline HBV-DNA level in (log~10~ copies/mL)Baseline ALT level (U/L)Intervention/Control (n)Treatment initiation (Gestational weeks) (Intervention/control)Treatment discontinuation (Postpartum weeks)Study designRisk of biasHan *et al*.^23^27 (20-35)/28 (20-38) (range)39.4 (34.1-41.6)/ 39.5 (33.5-41.3) (range)21.45 (7.6-407.0)/ 17.1 (5.2-513.5) (range)257/10524.4/29Stopped at postnatal months 1--3, while patients with CHB continued anti-HBV therapy.Cohort9Hu *et al*.^20^23.23±3.25/24.36±3.127.50±0.47/7.38±0.66 (log~10~ IU/mL)39±16/42±2030/3014/28Continued antiviral therapyCohort8Liu *et al*.^22^27.88±3.73/28.31±3.817.67±0.79/7.46±0.7346.64±58.74/28.91±38.4824/322^nd^ trimester/ 3^rd^ trimesterLasted until the 4^th^ week postpartum (basic CHB treatment was continued).Cohort8Pan *et al*.^25^27.65±4.08/27.37±3.547.22±0.61/7.26±0.5568.6±103.6/36.4±39.766/9413-27/28-30No descriptionCohort8Wang *et al*.^24^29.31±3.82/29.31±3.827.53±0.81/7.53±0.8120.83±11.62/20.83±11.6221/2724/28Alter delivery, 40 continue antiviral therapy, while 8 dropped out 1 month postpartumCohort9Wang *et al*.^21^ (1)No description6.99±1.05/7.18±1.31 (log~10~ IU/mL)32.90±10.81/26.25±18.0920/2020/28No descriptionCohort8Wang *et al*.^21^ (2)No description6.99±1.05/7.26±1.17 (log~10~ IU/mL)32.90±10.81/32.30±16.0120/2020/32No descriptionCohort8Wang *et al*.^21^ (3)No description6.99±1.05/6.72±1.12 (log~10~ IU/mL)32.90±10.81/37.05±17.3120/2020/36No descriptionCohort8Wang *et al*.^21^ (4)No description7.21±1.32/7.18±1.31 (log~10~ IU/mL)35.55±21.34/26.25±18.0920/2024/28No descriptionCohort8Wang *et al.* ^21^ (5)No description7.21±1.32/7.26±1.17 (log~10~ IU/mL)35.55±21.34/32.30±16.0120/2024/32No descriptionCohort8Wang *et al*.^21^ (6)No description7.21±1.32/6.72±1.12 (log~10~ IU/mL)35.55±21.34/37.05±17.3120/2024/36No descriptionCohort8Wang *et al*.^18^ (1)No description2.22±0.36/2.63±0.59 (log~10~ IU/mL)33.00±10.84/27.05±17.4220/2020/28No descriptionCohort8Wang *et al*.^18^ (2)No description2.22±0.36/4.08±0.88 (log~10~ IU/mL)33.00±10.84/32.55±15.4420/2020/32No descriptionCohort8Wang *et al*.^18^ (3)No description2.22±0.36/4.90±0.70 (log~10~ IU/mL)33.00±10.84/37.10±17.1920/2020/36No descriptionCohort8Wang *et al.* ^18^ (4)No description2.47±0.48/2.63±0.59 (log~10~ IU/mL)35.65±20.82/27.05±17.4220/2024/28No descriptionCohort8Wang *et al*.^18^ (5)No description2.47±0.48/4.08±0.88 (log~10~ IU/mL)35.65±20.82/32.55±15.4420/2024/32No descriptionCohort8Wang *et al*.^18^ (6)No description2.47±0.48/4.90±0.70 (log~10~ IU/mL)35.65±20.82/37.10±17.1920/2024/36No descriptionCohort8Yin and Wang^19^29.48±5.27/28.91±6.357.93±0.41/7.85±0.51 (log~10~ IU/mL)No description74/14924/2842 days after deliveryCohort8Zhou *et al*.^17^27.43±6.72/28.07±5.267.52±0.63/7.43±0.7228.28-111.25/ 26.25-108.25 (quartile)49/6420/28After deliveryCohort8

Table 2Antiviral intervention initiated in the second trimester compared to the third trimester in maternal HBV-DNA (log10) before treatment.Study or subgroupSecond TrimesterThird TrimesterWeightMean DifferenceMean DifferenceMeanSDTotalMeanSDTotalIV, Fixed, 95% CIIV, Fixed, 95% CIHan *et al*.^23^7.910.752577.830.77510529.3%0.08 \[-0.09, 0.25\]![](1678-9946-rimtsp-62-S1678-9946202062013-ingf01.jpg)Hu *et al*.^20^8.251.22308.131.41302.0%0.12 \[-0.55, 0.79\]Liu *et al*.^22^7.670.79247.460.73328.0%0.21 \[-0.12, 0.54\]Pan *et al*.^25^7.220.61667.260.559426.2%-0.04 \[-0.22, 0.14\]Wang *et al*.^24^7.530.81217.530.81274.2%0.00 \[-0.46, 0.46\]Wang *et al*.^21^ (1)7.741.8207.932.06200.6%-0.19 \[-1.39, 1.01\]Wang *et al*.^21^ (2)7.741.8208.011.92200.7%-0.27 \[-1.42, 0.88\]Wang *et al*.^21^ (3)7.741.8207.471.87200.7%0.27 \[-0.87, 1.41\]Wang *et al*.^21^ (4)7.962.07207.932.06200.5%0.03 \[-1.25, 1.31\]Wang *et al.* ^21^ (5)7.962.07208.011.92200.6%-0.05 \[-1.29, 1.19\]Wang *et al*.^21^ (6)7.962.07207.471.87200.6%0.49 \[-0.73, 1.71\]Wang *et al*.^18^ (1)7.761.76207.981.9200.7%-0.22 \[-1.36, 0.92\]Wang *et al*.^18^ (2)7.761.76207.961.87200.7%-0.20 \[-1.33, 0.93\]Wang *et al*.^18^ (3)7.761.76207.41.65200.8%0.36 \[-0.70, 1.42\]Wang *et al.* ^18^ (4)7.891.91207.981.9200.6%-0.09 \[-1.27, 1.09\]Wang *et al*.^18^ (5)7.891.91207.961.87200.6%-0.07 \[-1.24, 1.10\]Wang *et al*.^18^ (6)7.891.91207.41.65200.7%0.49 \[-0.62, 1.60\]Yin and Wang^19^8.681.16748.61.261498.0%0.08 \[-0.25, 0.41\]Zhou *et al*.^17^7.520.63497.430.726414.3%0.09 \[-0.16, 0.34\]Total (95% CI)  761  741100%0.06 \[-0.04, 0.15\]Heterogeneity: Chi^2^ = 4.67; df = 18 (P = 1.00); I^2^ = 0%Test for overall effect: Z = 1.15 (P = 0.25)

Table 3Antiviral intervention initiated in the second trimester compared to the third trimester in maternal HBV-DNA (log10) prior to delivery.Study or subgroupSecond TrimesterThird TrimesterWeightMean DifferenceMean DifferenceMeanSDTotalMeanSDTotalIV,Randon,95% CIIV,Random,95% CIHan *et al*.^23^2.51.82573.31.61057.8%-0.80 \[-1.18, -0.42\]![](1678-9946-rimtsp-62-S1678-9946202062013-ingf02.jpg)Hu *et al*.^20^6.31.94306.422.0305.5%-0.12 \[-1.12, 0.88\]Pan *et al*.^25^4.121.02664.680.9948.0%-0.56 \[-0.87, -0.25\]Wang *et al*.^21^ (1)3.381.45204.161.6205.7%-0.78 \[-1.73, 0.17\]Wang *et al*.^21^ (2)3.381.45205.451.87205.4%-2.07 \[-3.11, -1.03\]Wang *et al*.^21^ (3)3.381.45205.981.67205.6%-2.60 \[-3.57, -1.63\]Wang *et al*.^21^ (4)3.681.42204.161.6205.8%-0.48 \[-1.42, 0.46\]Wang *et al*.^21^ (5)3.681.42205.451.87205.4%-1.77 \[-2.80, -0.74\]Wang *et al*.^21^ (6)3.681.42205.981.67205.7%-2.30 \[-3.26, -1.34\]Wang *et al*.^18^ (1)2.971.11203.381.34206.4%-0.41 \[-1.17, 0.35\]Wang *et al*.^18^ (2)2.971.11204.831.63206.0%-1.86 \[-2.72, -1.00\]Wang *et al*.^18^ (3)2.971.11205.651.45206.3%-2.68 \[-3.48, -1.88\]Wang *et al*.^18^ (4)3.221.23203.381.34206.3%-0.16 \[-0.96, 0.64\]Wang *et al.* ^18^ (5)3.221.23204.831.63205.9%-1.61 \[-2.50, -0.72\]Wang *et al*.^18^ (6)3.221.23205.651.45206.2%-2.43 \[-3.26, -1.60\]Yin and Wang^19^3.571.23744.051.281497.9%-0.48 \[-0.83, -0.13\]Total (95% CI)  667  618100%-1.27 \[-1.67, -0.87\]Heterogeneity: Tau^2^=0.51; Chi^2^=85.3; df=15(P\<0.00001); I^2^=82%Test for overall effect :Z=6.18(P\<0.00001)

Table 4Forest plot of antiviral intervention initiated in the second trimester compared to the third trimester with respect to maternal HBV-DNA (log10) prior to delivery (subgroups analyses according to different starting times).Study or subgroupSecond TrimesterThird TrimesterWeightMean DifferenceMean DifferenceMeanSDTotalMeanSDTotalIV,Fixed,95% CIIV,Fixed,95% CI4.1 20 w VS 28 w        ![](1678-9946-rimtsp-62-S1678-9946202062013-ingf03.jpg)Wang *et al*.^21^ (1)3.381.45204.161.6202.6%-0.78 \[-1.73, 0.17\]Wang *et al*.^18^ (1)2.971.11203.381.34204.1%-0.41 \[-1.17, 0.35\]Subtotal (95% CI)  40  406.7%-0.56 \[-1.15, 0.04\]Heterogeneity: Chi^2^ = 0.36, df = 1 (P = 0.55); I^2^ = 0%Test for overall effect: Z = 1.83 (P = 0.07)**4.2 20 w VS 32 w**Wang *et al*.^21^ (2)3.381.45205.451.87202.2%-2.07 \[-3.11, -1.03\]Wang *et al*.^18^ (2)2.971.11204.831.63203.2%-1.86 \[-2.72, -1.00\]Subtotal (95% CI)  40  405.4%-1.95 \[-2.61, -1.28\]Heterogeneity: Chi^2^ = 0.09, df = 1 (P = 0.76); I^2^ = 0%Test for overall effect: Z = 5.74 (P \< 0.00001)**4.3 20 w VS 36 w**Wang *et al*.^21^ (3)3.381.45205.981.67202.5%-2.60 \[-3.57, -1.63\]Wang *et al*.^18^ (3)2.971.11205.651.45203.7%-2.68 \[-3.48, -1.88\]Subtotal (95% CI)  40  406.2%-2.65 \[-3.26, -2.03\]Heterogeneity: Chi^2^ = 0.02, df = 1 (P = 0.90); I^2^ = 0%Test for overall effect: Z = 8.41 (P \< 0.00001)4.4 24 w VS 28 wWang *et al*.^21^ (4)3.681.42204.161.6202.7%-0.48 \[-1.42, 0.46\]Wang *et al*.^18^ (4)3.221.23203.381.34203.7%-0.16 \[-0.96, 0.64\]Yin and Wang^19^3.571.23744.051.2814919.6%-0.48 \[-0.83, -0.13\]Subtotal (95% CI)  114  18926.1%-0.43 \[-0.74, -0.13\]Heterogeneity: Chi^2^ = 0.53, df = 2 (P = 0.77); I^2^ = 0%Test for overall effect: Z = 2.82 (P = 0.005)4.5 24 w VS 32 wWang *et al*.^21^ (5)3.681.42205.451.87202.2%-1.77 \[-2.80, -0.74\]Wang *et al*.^18^ (5)3.221.23204.831.63203.0%-1.61 \[-2.50, -0.72\]Subtotal (95% CI)  40  405.2%-1.68 \[-2.35, -1.00\]Heterogeneity: Chi^2^ = 0.05, df = 1 (P = 0.82); I^2^ = 0%Test for overall effect: Z = 4.87 (P \< 0.00001)4.6 24 w VS 36 wWang *et al*.^21^ (6)3.681.42205.981.67202.6%-2.30 \[-3.26, -1.34\]Wang *et al*.^18^ (6)3.221.23205.651.45203.4%-2.43 \[-3.26, -1.60\]Subtotal (95% CI)  40  406.0%-2.37 \[-3.00, -1.74\]Heterogeneity: Chi^2^ = 0.04, df = 1 (P = 0.84); I^2^ = 0%Test for overall effect: Z = 7.39 (P \< 0.00001)**4.7 the second trimester vs the third trimester**Han *et al*.^23^2.51.82573.31.610516.7%-0.80 \[-1.18, -0.42\]Hu *et al*.^20^6.31.94306.422.0302.4%-0.12 \[-1.12, 0.88\]Pan *et al*.^25^4.121.02664.680.99425.3%-0.56 \[-0.87, -0.25\]Subtotal (95% CI)  353  22944.4%-0.63 \[-0.86, -0.40\]Heterogeneity: Chi^2^ = 1.99; df = 2 (P = 0.37); I^2^ = 0%Test for overall effect: Z = 5.31 (P \< 0.00001)Total (95% CI)  667  618100%-0.93 \[-1.08, -0.77\]Heterogeneity: Chi^2^ = 85.30; df = 15 (P \< 0.00001); I^2^ = 82%Test for overall effect: Z = 11.81 (P \< 0.00001)Test for subgroup differences: Chi^2^ = 82.22; df = 6 (P \< 0.00001) ; I^2^ = 92.7%

Thus, compared to the beginning of treatment in the third trimester, the onset of antiviral intervention in the second trimester distinctly reduced maternal HBV-DNA levels, and this effect was related to the antiviral treatment.

Relative risk of mother-to-child transmission with antiviral therapy initiation in the second vs. third trimester
-----------------------------------------------------------------------------------------------------------------

Among the 1,502 enrolled pregnant women, 761 began to receive antiviral treatment in the second trimester, while 741 received it in the third trimester. The percentages of newborns with HBsAg or HBV-DNA seropositivity in the second trimester group and third trimester group were 0% (0/761) and 1.08% (8/741), respectively. The rate of HBV MTCT in the second trimester group was similar to the one in the third trimester group, with no significant difference between the groups (*RR* =0.19, 95% *CI* 0.03-1.08, *I* ^2^=0%, *P* =0.06, [Table 5](#t5){ref-type="table"}).

Table 5Forest plot of HBV MTCT rate (the second trimester or the third trimester).Study or SubgroupSecond TrimesterThird TrimesterWeightRisk RatioRisk RatioEventsTotalEventsTotalM-H,Fixed,95% CIM-H,Fixed,95% CIHan *et al*.^23^02570105 Not estimable![](1678-9946-rimtsp-62-S1678-9946202062013-ingf04.jpg)Hu *et al*.^20^03013017.8%0.33 \[0.01, 7.87\]Liu *et al*.^22^02423225.5%0.26 \[0.01, 5.26\]Pan *et al*.^25^066094 Not estimableWang *et al*.^24^021027 Not estimableWang *et al*.^21^ (1)020020 Not estimableWang *et al*.^21^ (2)020020 Not estimableWang *et al*.^21^ (3)020020 Not estimableWang *et al*.^21^ (4)020020 Not estimableWang *et al*.^21^ (5)020020 Not estimableWang *et al*.^21^ (6)020020 Not estimableWang *et al*.^18^ (1)020020 Not estimableWang *et al*.^18^ (2)020020 Not estimableWang *et al*.^18^ (3)020020 Not estimableWang *et al*.^18^ (4)020020 Not estimableWang *et al*.^18^ (5)020020 Not estimableWang *et al*.^18^ (6)020020 Not estimableYin and Wang^19^0740149 Not estimableZhou *et al*.^17^04956456.7%0.12 \[0.01, 2.09\]Total (95% CI) 761 741100%0.19 \[0.03, 1.08\]Total events0 8   Heterogeneity: Chi^2^ = 0.27; df = 2 (P = 0.87); I^2^ = 0%Test for overall effect: Z = 1.87 (P = 0.06)

To compare the effects of different antiviral drugs initiation times on HBV MTCT rates, we divided the data into eight subgroups according to the time at which the intervention was initiated ([Table 6](#t6){ref-type="table"} ). The results of the different subgroups suggested that different durations of antiviral treatment led to similar incidences of HBV MTCT (*P* \>0.05).

Table 6Forest plot on the rate of mother-to-child hepatitis B virus transmission (subgroup analyses according to different starting times)Study or SubgroupSecond TrimesterThird TrimesterWeightRisk RatioRisk RatioEventsTotalEventsTotalM-H,Fixed,95% CIM-H,Fixed,95% CI6.1 14 w VS 28 w![](1678-9946-rimtsp-62-S1678-9946202062013-ingf05.jpg)Hu *et al*.^20^03013017.9%0.33 \[0.01, 7.87\]Subtotal (95% CI) 30 3017.9%0.33 \[0.01, 7.87\]Total events0 1   Heterogeneity: Not applicableTest for overall effect: Z = 0.68 (P = 0.50)**6.2 20 w VS 28 W**Zhou *et al*.^17^04956556.5%0.12 \[0.01, 2.12\]Wang *et al*.^21^ (1)020020 Not estimableWang *et al*.^18^ (1)020020 Not estimableSubtotal (95% CI) 89 10556.5%0.12 \[0.01, 2.12\]Total events0 5   Heterogeneity: Not applicableTest for overall effect: Z = 1.45 (P = 0.15)**6.3 20 w VS 32 w**Wang *et al*.^18^ (2)020020 Not estimableWang *et al*.^21^ (2)020020 Not estimableSubtotal (95% CI) 40 40 Not estimableTotal events0 0   Heterogeneity: Not applicableTest for overall effect: Not applicable**6.4 20 w VS 36 w**Wang *et al*.^21^ (3)020020 Not estimableWang *et al*.^18^ (3)020020 Not estimableSubtotal (95% CI) 40 40 Not estimableTotal events0 0   Heterogeneity: Not applicableTest for overall effect: Not applicable**6.5 24 w VS 28 w**Wang *et al*.^24^021027 Not estimableYin and Wang^19^0740149 Not estimableWang *et al*.^21^ (4)020020 Not estimableWang *et al*.^18^ (4)020020 Not estimableSubtotal (95% CI) 135 216 Not estimableTotal events0 0   Heterogeneity: Not applicableTest for overall effect: Not applicable**6.6 24 w VS 32 w**Wang *et al*.^18^ (5)020020 Not estimableWang *et al*.^21^ (5)020020 Not estimableSubtotal (95% CI) 40 40 Not estimableTotal events0 0   Heterogeneity: Not applicableTest for overall effect: Not applicable**6.7 24 w VS 36 w**Wang *et al*.^18^ (6)020020 Not estimableWang *et al*.^21^ (6)020020 Not estimableSubtotal (95% CI) 40 40 Not estimableTotal events0 0   Heterogeneity: Not applicableTest for overall effect: Not applicable**6.8 the second trimester and the third trimester**Liu *et al*.^22^02423225.7%0.26 \[0.01, 5.26\]Pan *et al*.^25^066094 Not estimableHan *et al*.^23^02570105 Not estimableSubtotal (95% CI) 347 23125.7%0.26 \[0.01, 5.26\]Total events0 2   Heterogeneity: Not applicableTest for overall effect: Z = 0.87 (P = 0.38)Total (95% CI) 761 742100%0.20 \[0.03, 1.09\]Total events0 8   Heterogeneity: Chi^2^ = 0.26; df = 2 (P = 0.88); I^2^ = 0%Test for overall effect: Z = 1.86 (P = 0.06)Test for subgroup differences: Chi^2^ = 0.25; df = 2 (P = 0.88) ; I^2^ = 0%

To assess whether HBsAg seropositivity and HBV-DNA seropositivity were equivalent endpoints for the evaluation of HBV MTCT, we split the data into two subgroups. Among the nine included articles, eight papers^[@B17]\ -\ [@B19],\ [@B21]\ -\ [@B25]^ reported the HBsAg seropositivity of the infants, while seven papers^[@B17],\ [@B18],\ [@B21]\ -\ [@B25]^ reported the HBV-DNA seropositivity in the infants. In the HBsAg group, the HBV MTCT rates in the second trimester and the third trimester were 0% (0/731) and 0.98% (7/711), respectively. The rate of HBV MTCT in the second trimester was not significantly lower than the one in the third trimester ( *RR* =0.16, *95% CI* 0.02-1.28, *I* ^2^=0%, *P* =0.08) ([Table 7](#t7){ref-type="table"}). In the HBV-DNA seropositivity group, the HBV MTCT rates in the second and third trimesters were 0% (0/657) and 0.53% (3/562), respectively ([Table 7](#t7){ref-type="table"}), with no significant difference between the trimesters (*RR* =0.19, *95% CI* 0.01-3.51, *P* =0.26). Thus, with regard to HBV MTCT prevention, there is no significant difference in MTCT rates when HBsAg with respect to HBV-DNA seropositivity was used as the outcome.

Table 7Forest plot on the rate of mother-to-child hepatitis B virus transmission (HBsAg seropositivity or HBV-DNA seropositivity).Study or SubgroupSecond TrimesterThird TrimesterWeightRisk RatioRisk RatioEventsTotalEventsTotalM-H,Fixed,95% CIM-H,Fixed,95% CI**7.1 HBsAg seropositivity** ![](1678-9946-rimtsp-62-S1678-9946202062013-ingf06.jpg)4.4.1 HBsAg seropositivity Han *et al*.^23^02570105 Not estimableLiu *et al*.^22^02423221.6%0.26 \[0.01, 5.26\]Pan *et al*.^25^066094 Not estimableWang *et al*.^24^021027 Not estimableWang *et al*.^21^ (1)020020 Not estimableWang *et al*.^21^ (2)020020 Not estimableWang *et al*.^21^ (3)020020 Not estimableWang *et al*.^21^ (4)020020 Not estimableWang *et al*.^21^ (5)020020 Not estimableWang *et al*.^21^ (6)020020 Not estimableWang *et al*.^18^ (1)020020 Not estimableWang *et al.* ^18^ (2)020020 Not estimableWang *et al*.^18^ (3)020020 Not estimableWang *et al*.^18^ (4)020020 Not estimableWang *et al*.^18^ (5)020020 Not estimableWang *et al*.^18^ (6)020020 Not estimableYin and Wang^19^0740149 Not estimableZhou *et al*.^17^04956447.9%0.12 \[0.01, 2.09\]Subtotal (95% CI) 731 71169.5%0.16 \[0.02, 1.28\]Total events      Heterogeneity: Chi^2^ = 0.15; df = 1 (P = 0.70); I^2^ = 0%Test for overall effect: Z = 1.73 (P = 0.08)**7.2 HBV DNA seropositivity** Han *et al*.^23^02570105 Not estimableLiu *et al*.^22^024032 Not estimablePan *et al*.^25^066094 Not estimableWang *et al*.^24^021027 Not estimableWang *et al*.^21^ (1)020020 Not estimableWang *et al*.^21^ (2)020020 Not estimableWang *et al*.^21^ (3)020020 Not estimableWang *et al*.^21^ (4)020020 Not estimableWang *et al*.^21^ (5)020020 Not estimableWang *et al*.^21^ (6)020020 Not estimableWang *et al*.^18^ (1)020020 Not estimableWang *et al*.^18^ (2)020020 Not estimableWang *et al*.^18^ (3)020020 Not estimableWang *et al*.^18^ (4)020020 Not estimableWang *et al*.^18^ (5)020020 Not estimableWang *et al*.^18^ (6)020020 Not estimableZhou *et al*.^17^04936430.5%0.19 \[0.01, 3.51\]Subtotal (95% CI) 657 56230.5%0.19 \[0.01, 3.51\]Total events0 3   Heterogeneity: Not applicableTest for overall effect: Z = 1.12 (P = 0.26)Total (95% CI) 1,388 1,273100%0.17 \[0.03, 0.92\]Total events0 10   Heterogeneity: Chi^2^ = 0.15; df = 2 (P = 0.93); I^2^ = 0%Test for overall effect: Z = 2.06 (P = 0.04)Test for subgroup differences: Chi^2^ = 0.00; df = 1 (P = 0.94) ; I^2^ = 0%

DISCUSSION
==========

This meta-analysis had two major findings. Firstly, compared to the treatment initiated in the third trimester, the antiviral intervention initiated in the second trimester could distinctly reduce maternal HBV-DNA levels, and this effect was closely related to the time of initiation. In addition, second-trimester and third-trimester initiations of antiviral treatment yielded similar incidences of HBV MTCT, irrespective of the initiation time and the different studied outcomes.

Lamivudine, LdT and TDF are equivalent in terms of antiviral efficacy^[@B6],\ [@B26]^. Hence, in our study, their effects were merged and directly compared. In addition, intrauterine infection can be almost perfectly prevented when the HBV-DNA load of the mother is \< 10^4^ copies/mL (10^3^ IU/mL)^[@B27]\ -\ [@B29]^, which is considered a safety maternal pre-delivery HBV-DNA threshold for HBV MTCT prevention. Among the included studies, the maternal pre-delivery HBV-DNA levels in mothers that began antiviral therapy in the second trimester were approximately 3 log~10~ copies/mL^[@B18],\ [@B19],\ [@B21]^, while the corresponding values in the third trimester were approximately 4 log~10~ copies/mL^[@B18],\ [@B19],\ [@B21],\ [@B25]^. Both groups were within the safety threshold. This finding could explain why the antiviral therapy initiated in the second trimester, in contrast with the one initiated in the third trimester, could significantly reduce the maternal pre-delivery HBV-DNA levels without changing MTCT.

However, some results should not be ignored. The *P* value for the difference in HBV MTCT rate between the second and the third trimester group was 0.06, which was close to the threshold for a statistically significant difference (0.05). Furthermore, in the included studies, the average maternal HBV- DNA level before treatment was approximately 8 log~10~ copies/mL. In mothers who began the antiviral intervention in the third trimester, the average maternal HBV- DNA level prior to delivery was approximately 4 log~10~ copies/mL, close to the safety threshold for HBV MTCT prevention. These findings suggest that the initiation of antiviral treatment can be delayed until the third trimester in mothers in whom HBV-DNA levels are less than or equal to 8 log~10~ copies/mL. This type of treatment with a shorter duration, fewer side effects and lower financial burden, will be more suitable than second trimester-initiated treatment for the widespread use to prevent HBV MTCT. However, if the HBV-DNA level in a mother exceeds 8 log~10~ copies/mL and antiviral therapy is initiated in the third trimester, the risk of HBV MTCT may increase. Larger sample size cohort studies, including subjects with higher maternal HBV-DNA levels are needed to verify this hypothesis.

Recently, two similar meta-analyses compared the efficacy of antiviral treatment started in the second trimester with the one strated on the third trimester for preventing HBV MTCT. In 2014, a study^[@B30]^ reported that antiviral intervention is effective in preventing HBV MTCT whether it is started in the second or the third trimester, with no significant difference in the rate of vertical transmission. In 2018, another study^[@B6]^ reported that antiviral intervention initiated in the second trimester might be better than the one initiated in the third trimester, as indicated by the HBV-DNA seropositivity rather than the HBsAg seropositivity in infants. In the latter study, the time to diagnosis of MTCT was within 24 h after delivery, which may have led to an overestimation of the MTCT rate^[@B30]\ -\ [@B32]^. Therefore, in our study, MTCT was considered to have occurred if HBsAg positivity was observed or if HBV- DNA levels were detectable when infants were seven to 12 months old.

This meta-analysis has four advantages. Above all, we searched for comprehensive databases, updated the included articles and merged the effects of different antiviral drugs. Moreover, all the included studies were parallel control trials, which have greater power than single-arm studies. Most importantly, this study is the first to interpret why initiating antiviral therapy in the second trimester rather than in the third trimester can distinctly reduce maternal pre-delivery HBV-DNA levels without changing MTCT. Finally, we divided maternal HBV-DNA levels prior to delivery and the HBV MTCT incidences into several subgroups according to specific drug intervention times to further explore associations of specific treatment durations with the examined outcomes.

The present study also has some limitations. Firstly, there is a lack of high-quality RCTs and cohort studies with larger sample sizes because of ethical restrictions, among other reasons. Secondly, different countries have different vaccination methods and MTCT diagnostic criteria. To improve the comparability, our inclusion criteria limited studies carried out with different methods. Thus, even though there was no language restriction, all the study participants were Asian. These limitations need to be considered when evaluating the conclusions.

CONCLUSION
==========

For pregnant women with HBV-DNA levels less than or equal to 8 log~10~ copies/mL initiation of antiviral treatment can be delayed until the third trimester of pregnancy.
